0001209191-23-009272.txt : 20230214
0001209191-23-009272.hdr.sgml : 20230214
20230214172544
ACCESSION NUMBER: 0001209191-23-009272
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210210
FILED AS OF DATE: 20230214
DATE AS OF CHANGE: 20230214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Neil
CENTRAL INDEX KEY: 0001742485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 23631907
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3160 PORTER DR.
STREET 2: SUITE 250
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 3160 PORTER DR.
STREET 2: SUITE 250
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-10
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001742485
Kumar Neil
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
PALO ALTO
CA
94304
1
1
0
0
CEO and President
Stock Option (Right to Buy)
11.41
2023-02-10
4
A
0
624652
0.00
A
2033-02-09
Common Stock
624652
624652
D
Restricted Stock Units
2023-02-10
4
A
0
536704
0.00
A
Common Stock
536704
536704
D
The shares subject to this option vest and become exercisable in 48 equal monthly installments after February 10, 2023, such that all of the shares subject to the option shall be vested and exercisable on February 10, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date.
/s/Brian C. Stephenson, Attorney-in-fact
2023-02-14